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Background: GATA-2 transcription factor deficiency has recently been described in patients with a propensity
towards myeloid malignancy associated with other highly variable phenotypic features: chronic leukocytopenias
(dendritic cell-, monocyto-, granulocyto-, lymphocytopenia), increased susceptibility to infections, lymphatic
vasculature abnormalities, and sensorineural deafness. Patients often suffer from opportunistic respiratory
infections; chronic pulmonary changes have been found in advanced disease.
Case presentation: We present a case of a 17-year-old previously healthy Caucasian male who was admitted to
the hospital with fever, malaise, headache, cough and dyspnea. A chest X-ray revealed bilateral interstitial infiltrates
and pneumonia was diagnosed. Despite prompt clinical improvement under antibiotic therapy, interstitial changes
remained stable. A high resolution computer tomography showed severe diffuse parenchymal lung disease, while
the patient’s pulmonary function tests were normal and he was asymptomatic. Lung tissue biopsy revealed chronic
reparative and resorptive reaction with organizing vasculitis. At the time of the initial presentation to the hospital,
serological signs of acute infection with Epstein-Barr virus (EBV) were present; EBV viremia with atypical serological
response persisted during two-year follow up. No other infectious agents were found. Marked monocytopenia
combined with B-cell lymphopenia led to a suspicion of GATA-2 deficiency. Diagnosis was confirmed by detection
of the previously published heterozygous mutation in GATA2 (c.1081 C > T, p.R361C). The patient’s brother and
father were both carriers of the same genetic defect. The brother had no clinically relevant ailments despite
leukocyte changes similar to the index patient. The father suffered from spondylarthritis, and apart from B-cell
lymphopenia, no other changes within the leukocyte pool were seen.
Conclusion: We conclude that a diagnosis of GATA-2 deficiency should be considered in all patients with diffuse
parenchymal lung disease presenting together with leukocytopenia, namely monocyto-, dendritic cell- and B-lymphopenia,
irrespective of severity of the clinical phenotype. Genetic counseling and screening for GATA2 mutations within the patient’s
family should be provided as the phenotype is highly variable and carriers without apparent immunodeficiency are still in
danger of developing myeloid malignancy. A prompt recognition of this rare condition helps to direct clinical treatment
strategies and follow-up procedures.
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Defects of transcription factor GATA-2 have recently been
identified in a few overlapping phenotypes associated with
myeloid malignancies: dendritic cell, monocyte, B- and
NK-cell deficiency; MonoMAC syndrome (monocytopenia
with Mycobacterium avium complex infections); Ember-
ger syndrome (early onset primary lymphedema, multiple
warts, sensorineural deafness, dysmorphism); and familial
MDS/AML with no additional known phenotype. These
syndromes share autosomal-dominant inheritance with
variable manifestation of immunodeficiency [1-9]. The re-
spiratory tract is frequently affected by viral, fungal or
mycobacterial infections. Chronic lung tissue changes and
pulmonary alveolar proteinosis (PAP), as well as pulmon-
ary arterial hypertension, have been described in adult pa-
tients [1,7-9].
We present an adolescent male with GATA-2 deficiency
and early manifestation of diffuse parenchymal lung diseaseFigure 1 Pulmonary changes in the index patient. A: Diffuse bilateral lin
involvement (chest X-ray). B: Diffuse subpleural fibrotic changes – honeyco
and bronchectasis (red asterisk) in the upper lobes (high-resolution compu
fibrosis and cystic rearrangement (green arrows) and cholesterol clefts (blu
original magnification 50x). D: Thickened arterial wall, destruction of the ela
the upper left lobe (elastin tissue stain; original magnification 250x).(DPLD) as well as an atypical course of Epstein-Barr virus
(EBV) infection.
Case presentation
A 17-year-old Caucasian male presented to the hospital with
acute fever, malaise, headache, cough and dyspnea. A bilat-
eral pneumonia with signs of systemic inflammation corre-
sponding to bacterial infection (C-reactive protein 210 mg/l)
was diagnosed and antibiotic treatment initiated. No causa-
tive microorganism was identified. Despite rapid clinical
improvement, chest X-ray showed persistent interstitial
changes (Figure 1A). A subsequent high-resolution com-
puter tomography (HRCT) revealed marked lung damage
suggestive of bronchiectasis with peribronchitis, fibrotisa-
tion, subpleural cystic remodeling (honey-combing) and em-
physema (Figure 1B). Interestingly, pulmonary function tests
showed normal vital capacity, total lung capacity as well as
diffusing capacity (Table 1). Thus, we detected chronic lungear and reticular opacities, compatible with interstitial pulmonary
mb (black asterisk), areas of subpleural consolidations (blue asterisk)
ter tomography scan). C: Chronic reparative and resorptive reaction:
e arrows) in the upper left lobe (hematoxylin and eosin tissue stain;
stic layer, thrombosis showing organizing vasculitis (red arrows) in
Table 1 Results of pulmonary function tests
Initial investigation After 2-year follow-up
FVC 4.58 l (85%) 4.82 l (81%)
FEV1 4.48 l/min (101%) 4.45 l/min (93%)
MEF50 7.32 l/min (140%) 7.17 l/min (121%)
TLC 6.14 l (92%) 6.09 l (78%)
DLCO 87% 81%
Legend: The first examination was performed two weeks after disease
manifestation, there were more than 10 tests performed in the follow-up,
all showing similar values. The numbers are related to normal values
(parenthesis); the reference cohort has changed during the follow-up
(< 18 and > 18 years of age). The shape of expiratory/inspiratory flow curve
suggested intermittently mild periphery obstruction. Abbreviations:
FVC Forced vital capacity, FEV1 Forced expiratory volume in 1 second,
MEF Maximal mid-expiratory flow, TLC Total lung capacity, DLCO Diffusing
lung capacity.
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of pneumonia in a previously healthy boy. Further investiga-
tions to unfold the cause for the diffuse parenchymal lung
disease were initiated.
A complete blood count showed leukocytopenia with
marked monocytopenia (Table 2). Immunological assays
detected B-cell lymphopenia with predominance of
memory B cells. Despite the very low numbers of B cells,
normal serum immunoglobulin levels of IgM and IgA
and increased levels of IgG were present (23.6 g/l). Anti-
body response to routine vaccination was normal. No
serum autoantibodies were found. Functional testing of
granulocytes (respiratory burst test: analysis of the ability
of granulocytes to release reactive oxygen species after
in vitro stimulation) and of T cells (evaluation of prolif-
erative response of T cells to various in vitro stimuli)
excluded chronic granulomatous disease and T-cell pro-
liferation defects.
Serology corresponded with primary EBV infection
(Table 3). However, the EBV viral load in peripheral blood
was low. Bronchoalveolar lavage (BAL) showed EBV pres-







T cells (CD3+) 0.659 (85.3**)
B cells (CD19+) 0.015 (1.9**)
NK cells (CD56 + 16+) 0.085 (11.0**)
CD4/8 index 1.3
Legend: The initial leuko- and lymphopenia resolved; the profound monocyto- and
phenotype. Myeloid as well as plasmacytoid dendritic cells were missing. In the par
respectively, are shown.BAL fluid showed lymphocytosis with predominance of
CD8pos with increased HLA-DR expression (especially on
CD3pos8pos); alveolar macrophages were present, CD1apos
cells were not detected. No PAS (Periodic Acid–Schiff)
positive material was evident in the alveolar macrophages
(Table 4).
Neither bacterial, fungal, mycobacterial (including non-
tuberculous mycobacteria) nor viral (cytomegalovirus, hu-
man herpes virus 6, varicella zoster virus, human herpes
virus, respiratory syntitial virus, influenza, adenovirus, en-
terovirus, coronavirus, parainfluenza, human rhinovirus,
human metapneumovirus, bokavirus and papillomavirus
tested) infection was revealed via culture, serology or mo-
lecular genetic testing in peripheral blood and bronchoal-
veolar fluid. Hence, the extensive microbiological analysis
revealed only the presence of EBV in peripheral blood and
lungs.
Histopathological investigation of the lung parenchyma
was prompted. Thoracoscopic lung biopsy from a severely
affected region of the right upper lobe showed fibrosis,
cystic rearrangement and cholesterol clefts with signs of
organizing pneumonia and vasculitis (Figure 1 C, D). In-
flammatory infiltration was predominantly lymphoplas-
mocytic with presence of activated macrophages. No
changes compatible with pulmonary alveolar proteinosis
or other alveolar filling disorder were seen. Despite an
EBV presence (2300 copies/10.000 genomic equivalents,
g.e.) in the lung tissue found with polymerase chain reac-
tion, hybridization probes for EBV-encoded small RNA
(EBER) were negative in the histology slides. Thus, no
clear relationship between EBV and the histopathological
parenchymal changes could be stated.
Given the severe affliction of the lung parenchyma with fi-
brotic remodeling, ongoing inflammation with activated
CD8pos T cells in the bronchoalveolar fluid and lack of clear
evidence for an infectious cause, a treatment with an oral
steroid was initiated to suppress further tissue destruction.
A prophylactic antibiotic (azithromycin) was added and theAfter 2-year
follow-up
Normal values
× 10^9/l (%) × 10^9/l (%)
5.4 4.0 - 10.0
0.028 (0.5*) 0.12 - 1.0 (3 - 10*)
2.120 (39.3*) 1.0 - 3.3 (25 - 33*)
1.696 (80.0**) 2.0 - 6.5 (55 - 88**)
0.042 (2.0**) 0.4 - 3.3 (11 - 45**)
0.382 (18.0**) 0.1 - 1.0 (6 - 26**)
1.7 1 - 3
B-cell lymphopenia persisted. The B cells were predominantly of memory
enthesis percentage of cells out of (*) leukocytes and (**) lymphocytes,
Table 3 Serologic and molecular genetic analysis of Epstein-Barr virus infection
Initial investigation After 2-year follow-up
Anti-VCA IgG U/ml 63 >750
Anti-VCA IgM U/ml >160 47
Anti-EA-D IgG U/ml 22 >150
Anti-EBNA 1 IgG U/ml Negative Negative
Viral load in PB Copies/10000 g.e 288 31
Viral load in BAL Copies/ml 22000 6000
Abbreviations: VCA viral capsid antigen, EA-D early antigen component, EBNA 1 Epstein-Barr virus nuclear antigen 1, PB peripheral blood, BAL bronchoalveolar fluid,
g.e. genomic equivalent.
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malized and signs of systemic inflammation regressed. After
6 months a stable finding was documented via HRCT and
no clinical symptoms were present. The EBV viral load
remained low in peripheral blood. Minimal presence of the
virus was seen in repeated BAL. However, the serological
signs of active EBV infection persisted and no EBNA anti-
bodies were detected at the follow up. No lymphoprolifera-
tion was present and the patient remained asymptomatic.
The condition was classified as persistent EBV viremia ac-
companied by an atypical serological response. Molecular
genetic testing of SH2D1A was carried out. A normal result
excluded X-linked lymphoproliferative disease, the most
common inborn cause of abnormal immunological reaction
to EBV infection. Details on other possible genetic causes,
not yet tested in our patient, are in the Discussion.
The patient has a history of occasional uncomplicated
respiratory infections; At the age of 13 years he suffered
from acute bronchitis, a chest X-ray was performed and
retrospective analysis of the image showed some intersti-
tial changes present already at that time. Monocytopenia
was documented as early as at the age of 10 years.
The persistent profound monocytopenia and B- lympho-
cytopenia at follow up prompted GATA2 sequencing. The
diagnosis of GATA-2 deficiency was confirmed by the find-
ing of a known heterozygous pathogenic variation c.1081
C >T (p.R361C) [10]. Myeloid malignancy was excluded by
morphological, flow cytometric and cytogenetic analysis of
the bone marrow aspirate. Detailed immunophenotypic ana-
lysis of the bone marrow showed suppression of CD34pos
and CD117pos precursors; impairment of B-cell lineage
(only 1.4% B cells were present, out of those plasma cellsTable 4 Cytology analysis of bronchoalveolar fluid from
the initial bronchoscopy investigation
Lymphocytes 60.4% of leukocytes
CD3 + DR+ 35% of CD3+ cells
CD4/8 ratio 0.6
Neutrophile granulocytes 6.8% of leukocytes
Alveolar macrophages 31.6% of leukocytes
Plasmatic cells 1.2% of leukocytesconstituted 42% and mature CD20posCD10neg cells 37%,
the precursors CD34posCD10pos were scarce) and lower
percentage of monocytes as well as their progenitors
(CD14highCD45posSSCmed). Additional testing showed lack
of myeloid and plasmacytoid dendritic cells.
The immunosuppressive treatment was stopped and
the patient was further treated with prophylactic antibi-
otics and antimycotics. Vaccination against human papil-
lomavirus (HPV) was performed as recommended [9].
He has been monitored closely, including regular checks
of bone marrow aspirate for early detection of clonal
myeloid proliferation. In case of myelodysplasia, trans-
plantation of hematopoietic stem cells would be initi-
ated. After two years of follow-up the patient did not
develop any clinical symptoms. He was treated once for
Pseudomonas aeruginosa found in the bronchoalveolar
fluid detected in the second BAL analysis performed
6 months after the first one. Otherwise, there were no
clinical signs of increased susceptibility to infection. Pul-
monary function tests remained normal, no progression
of the pulmonary parenchyma affliction have been de-
tected so far (Tables 1, 2 and 3).
The same heterozygous mutation in GATA2 was found in
the patient’s 13-year-old brother and 45 year-old father,
whereas his mother was healthy. The brother had been
without any clinical symptoms so far, blood tests revealed
leukocytopenia and marked monocytopenia. HRCT scan
showed normal parenchyma, no EBV activity was docu-
mented. The father suffered from bilateral ankylosing spon-
dylitis (HLA-B27 positive). Apart from low B-cell numbers
(2.4% CD19pos cells of lymphocytes, with prevailing memory
phenotype: 70% CD27pos cells out of B cells; Norm< 47%)
no leukocyte count abnormalities were detected.
The lymphocyte changes in the three family members car-
rying the GATA2 mutation stimulated investigation of bone
marrow output. Newly emerging T and B cells can be
assessed via T-cell recombination circle (TREC) and kappa-
deleting element recombination circle (KREC) analysis in
the peripheral blood [11,12]. As expected, both siblings had
no detectable KREC copies in the peripheral blood, indicat-
ing severe impairment of B cell development. TREC analysis
showed normal results. Bone marrow examination of the
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with normal TREC copies. KREC copies were absent in the
peripheral blood of the father as well. The KREC/TREC
copies were normal in the unaffected mother.
Interestingly, DNA obtained from the newborn Guthrie
card of the younger brother was analyzed showing a nor-
mal amount of KREC/TREC copies. This indicates that
the impairment in B lymphocyte development occurred
postnatally.
Discussion
GATA-2 deficiency is a protean disease with a broad
spectrum of symptoms. Most of the patients present with
hematological abnormalities (cytopenias, early-onset mye-
loid malignancies) and an increased susceptibility to oppor-
tunistic infections [1-9]. In the recently published cohort of
57 patients treated at the National Institute of Health (NIH,
Bethesda, USA) [9] 70% of the patients had severe viral in-
fections, particularly infection with HPV (63%) presenting
with recalcitrant warts, condylomata, and/or dysplasia. Se-
vere herpesvirus infections were present in 35% of patients:
recurrent herpes stomatitis, esophagitis, genital infection,
severe varicella in 11% of cases, and cytomegalovirus pneu-
monia or disseminated disease. Interestingly, in 11% of pa-
tients persistent EBV viremia similar to our patient was
documented; in 2 patients EBV-positive skin tumors oc-
curred. Infection with non-tuberculous mycobacteria was
seen in 53%, severe bacterial infection was observed in 49%
and severe invasive fungal infection in 16% of the patients.
Eighteen percent of patients showed no increased suscepti-
bility to infection. Additionally, vascular/lymphatic defects
(venous thrombosis, lymphedema), sensorineural hearing
loss, miscarriages and hypothyroidism were found [1-9].
Pulmonary involvement in GATA-2 deficiency is fre-
quent, involving infections and PAP [1,3,8,9], particularly
in more advanced stages of the disease. In the NIH cohort,
79% and 63% of the patients had diffusion and ventilatory
defects, respectively. PAP was found in 18% and pulmon-
ary arterial hypertension in 9% of patients. Structural ab-
normalities included nodules, reticular and ground glass
opacities, subpleural blebbing, “crazy paving” , and para-
septal emphysema [9]. Similar picture could be seen in
our patient. The surprisingly normal pulmonary function
test results in our patient could possibly be explained by
localized affliction of the pulmonary tissue. The infiltrated
and fibrotic tissue decreased the elasticity of the lung par-
enchyma, however, there was still enough normal tissue
that kept the static volumes and transfer factor normal
(Table 1). Unfortunately, it is not possible to compare our
findings with other pediatric patients as the data on pul-
monary infliction in children are scarce. There were 24
children in the NIH cohort. Data on the pulmonary func-
tion tests were presented for only 6 of them (median age
at testing 16 years, range 12–17 years; median time fromdisease manifestation 2.5 years, range 0–16 years). All those
children suffered from myeloid malignancy, in four of them
a chronic infection with herpesviruses or mycobacteria spe-
cies was documented. Mild to severe diffusion defects were
found in all tested patients, in two children a bronchial ob-
struction was seen. No information on structural lung
changes in the affected children was provided [9].
The median age at initial presentation in the NIH cohort
was 20 years but was highly variable (range 5 months –
78 years). Of note, four individuals (7%) had no apparent
clinical manifestations as of the last follow-up (range 5–55
years). The proportion of patients without symptoms was
50% by age 20, 25% by age 30, and 16% by age 40 irre-
spective of the type of genetic change in GATA2. The
phenotype varied within families significantly [9]. This fact
strongly argues for a substantial impact of epigenetic, in-
fectious and environmental factors on disease manifest-
ation. Effects of germline or somatic mutations in other
genes may play a role as well. This may explain the vari-
ability of symptoms in the three individuals carrying the
same GATA2 mutation within our index family.
An intriguing issue is the etiology of the chronic dif-
fuse parenchymal lung tissue changes in our patient in
the absence of respiratory symptoms. The extensive in-
vestigations revealed only EBV presence in peripheral
blood as well as in pulmonary tissue without specific tis-
sue changes or clinically apparent EBV infection (e.g.
mononucleosis-like symptoms, lymphoproliferation). As
the patient presented with serological signs of acute EBV
infection whereas the pulmonary changes were chronic,
a decisive role of EBV in the pathogenesis of the pul-
monary tissue changes in our patient was improbable.
Possibly repeated mild infections in an environment of
impaired regulation of the endothelial nitric oxide syn-
thetase expression [13], defective phagocytosis and im-
paired GM-CSF signaling in pulmonary macrophages
[14,15] played a role in the pathogenesis of the chronic
pulmonary inflammatory changes.
Poor control of EBV replication resulting in persistent
EBV viremia irrespective of lung involvement is a known
phenomenon in GATA-2 deficient patients [1,7-9]. It has
been shown that the inability to confine viral infections in
patients with GATA-2 deficiency correlates well with the ex-
tent of cytopenias, namely with the lack of DC-, NK- and
CD4pos T-cells. Similarly, the defective antibody response at
more advanced stages is associated with B cell lymphopenia
[8,9]. However, with regards to the possible oligogenic eti-
ology of immunodeficiency in GATA-2 deficiency, impact of
other genes implicated in EBV control should be considered.
We have excluded only the most common syndrome – X-
linked lymphoproliferative disease type 1 caused by a defect
in an adapter protein SAP, involved in signalling of cell-cell
interactions. Other molecules implicated in EBV control en-
compass for example: the ubiquitously expressed XIAP with
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connections; the surface molecule CD27, important for
intercellular communication; the NK cell activating receptor
for antibody-dependent cell cytotoxicity (CD16), and mini-
chromosome maintenance 4 (MCM4) crucial for NK-cell
function; or IL-2-inducible T-cell kinase (ITK), coronin1A,
serine-threonine kinase (STK)4 and magnesium transporter,
MAGT1, indispensable for T-cell receptor signalling and T-
cell homeostasis [16].
The search for a GATA-2 defect in our patient was
prompted by the abnormalities in the leukocyte and
lymphocyte counts. Another serum marker useful in diag-
nostics as well as in monitoring of the disease progression
(correlating with cytopenia) is the stem cell growth Fms-
related tyrosine kinase 3 ligand (Flt3 ligand) [8]. We have
shown that the newborn screening using KREC/TREC ana-
lysis [17] cannot be used to screen for GATA-2 deficiency.
The prognosis of individuals with GATA2 mutations is
difficult to establish due to high clinical variability, incom-
plete penetrance and lack of close phenotype-genotype
correlation data [8,9,18]. Antibiotics (e.g. azithromycin)
and HPV vaccination are the recommended prophylactic
measures [9]. Use of steroids or other immunosuppressive
therapy is not indicated and exclusion of immunodefi-
ciency in DPLD prior to use is warranted. A large propor-
tion of patients will develop myeloid malignancy later in
life [1,7-9]. The only curative therapy is allogeneic
hematopoietic stem cell transplantation. Two patients
with GATA-2 deficiency with pulmonary involvement
transplanted for advanced MDS were reported to have
profited significantly from this procedure [7].
Conclusion
Diffuse parenchymal lung diseases are a heterogeneous
group of disorders with an often insidious onset of symp-
toms [19]. The underlying immunodeficiency may not be
apparent and an immunological and genetic work-up is re-
quired, in particular if abnormalities in peripheral leukocyte
counts are revealed. As demonstrated in our patient, an ab-
errant immune response to common respiratory infections
may result in diffuse lung disease with bronchial and bron-
chiolar damage, significant chronic changes of pulmonary
parenchyma and fibrotic remodeling. The structural changes
might be present prior to any severe infection.
Diffuse parenchymal lung disease may become the first
manifestation of the GATA-2 deficiency. Early genetic
diagnosis is critical to direct clinical management, prophy-
laxis, transplantation, and family screening.
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